Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports.
Guided Therapeutics Stock Performance
Shares of Guided Therapeutics stock remained flat at $0.29 during trading hours on Thursday. 1 shares of the stock traded hands, compared to its average volume of 5,585. The company’s fifty day moving average price is $0.26 and its 200-day moving average price is $0.27. The firm has a market cap of $28.00 million, a P/E ratio of -7.25 and a beta of 0.71. Guided Therapeutics has a fifty-two week low of $0.15 and a fifty-two week high of $0.54.
Guided Therapeutics Company Profile
Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non?invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.
The company secured 510(k) clearance from the U.S.
See Also
- Five stocks we like better than Guided Therapeutics
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
